Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The Critical Path Institute: transforming competitors into collaborators

Nature Reviews Drug Discovery volume 13, pages 785–786 (2014)Cite this article

Subjects

The Critical Path Institute brings scientists from regulatory agencies, industry and academia together to improve drug development and regulatory processes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Woodcock, J. & Woosley, R. The FDA Critical Path Initiative and its influence on new drug development. Annu. Rev. Med. 59, 1–12 (2008).

    Article  CAS  Google Scholar 

  2. Rogers, J. A. et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis. J. Pharmacokinet. Pharmacodyn. 39, 479–498 (2012).

    Article  Google Scholar 

  3. Yu, P. et al. Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiol. Aging 35, 808–818 (2014).

    Article  Google Scholar 

  4. Rudick, R. A. et al. Multiple Sclerosis Outcome Assessments Consortium: genesis and initial project plan. Mult. Scler. 20, 12–17 (2014).

    Article  Google Scholar 

  5. Walker, E. G. et al. Evolving global regulatory science through the voluntary submission of data: a 2013 assessment. Ther. Innovation Regul. Sci. 48, 236–245 (2014).

    Google Scholar 

Download references

Acknowledgements

M.B. would like to thank L. Hudson for her contributions to this article.

Author information

Authors and Affiliations

  1. President and CEO of the Critical Path Institute, 1730 East River Road, Tucson, Arizona, 85718, USA

    Martha Brumfield

Authors
  1. Martha Brumfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha Brumfield.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Supplementary information

Supplementary information S1 (table)

Progress in advancing drug development tools and methods by C-Path consortia (PDF 1411 kb)

Related links

Related links

FURTHER INFORMATION

CDISC

Coalition For Accelerating Standards and Therapies (CFAST

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brumfield, M. The Critical Path Institute: transforming competitors into collaborators. Nat Rev Drug Discov 13, 785–786 (2014). https://doi.org/10.1038/nrd4436

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4436

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research